SCHEMBL5887186

SCHEMBL5887186

COc1ccc(-c2[c]c3ccccc3o2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
KDM4E B2RXH2 4/20 0.43
MAOB P27338 3/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPT P10636 3/20 0.43
CYP3A4 P08684 2/20 0.43
HSD17B10 Q99714 2/20 0.43
LMNA P02545 2/20 0.43
ABCG2 Q9UNQ0 2/20 0.43
TNKS O95271 1/20 0.43
TP53 P04637 1/20 0.43
GLA P06280 1/20 0.43
THRB P10828 1/20 0.43
HPGD P15428 1/20 0.43
KCNA5 P22460 1/20 0.43
KCNH2 Q12809 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NLRP3 Q96P20 1/20 0.43
CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887205 0.83 LTA4H (0.40) NPC1RAB9AMAOBCA1CA2
SCHEMBL7117244 0.83 MAOB (0.46) NPC1RAB9AKDM4EMAOBALDH1A1
SCHEMBL27842852 0.80 CA1 (0.47) NPC1RAB9AKDM4EMAOBALDH1A1
SCHEMBL2118628 0.71 MAOA (0.36) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL5887130 0.70 AHR (0.42) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL3819482 0.66 APP (0.50) NPC1RAB9AKDM4EMAPTTP53
SCHEMBL2553284 0.66 CA12 (0.40) NPC1RAB9AKDM4EMAOBALDH1A1
SCHEMBL27529014 0.66 EGFR (0.47) NPC1RAB9AKDM4EMAOBALDH1A1
SCHEMBL291776 0.65 CA4 (0.68) NPC1RAB9AKDM4EALDH1A1LMNA
SCHEMBL17283658 0.65 CA4 (0.68) NPC1RAB9AKDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US claimed
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US disclosed
US-20060004195-A1 Alpha,beta-unsaturated esters and acids by stereoselective dehydration JANSSEN PHARMACEUTICA N.V. (BE) 2006-01-05 US disclosed
US-20050026903-A1 CCK-1 receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-03 US disclosed
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders JONES TODD K (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders CCKAR, CCKBR, NPY1R NPC1 1831/4885RAB9A 1054/4885KDM4E 3706/4885
US-20060004195-A1 Alpha,beta-unsaturated esters and acids by stereoselective dehydration CCKAR, CCKBR, FFAR1 NPC1 1514/4885RAB9A 1988/4885KDM4E 4599/4885
US-20050026903-A1 CCK-1 receptor modulators CCKAR, CCKBR, GLP1R NPC1 2930/4885RAB9A 1724/4885KDM4E 3040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.